Did REDUCE-IT have a formal extension study?

No formal open-label extension was conducted. Follow-up analyses were prespecified substudies of the original trial data, not new patient enrollment or continued randomized treatment.

How long did the cardiovascular benefit take to appear?

Kaplan-Meier curves separated within the first 12 months and continued diverging through the median 4.9-year follow-up, suggesting an early-onset mechanism beyond triglyceride lowering alone.

Was the mineral oil placebo a real problem?

It remains debated. The FDA concluded the benefit was too large to be explained by placebo effects alone. The EMA disagreed and declined approval. Sensitivity analyses suggest 3, 5 percentage points of the 25% relative risk reduction could be attributable to mineral oil.

Why did the STRENGTH trial fail to replicate REDUCE-IT?

STRENGTH used EPA plus DHA (not EPA alone) and a corn oil placebo (not mineral oil). Either or both differences could explain the divergent results. The question is unresolved.

Does icosapent ethyl cause atrial fibrillation?

REDUCE-IT reported a statistically significant increase in AF (5.3% vs. 3.9%, p=0.003). This is consistent with a broader meta-analysis showing dose-dependent AF risk with high-dose omega-3 fatty acids.

Is the bleeding risk clinically significant?

Serious bleeding was numerically higher (2.7% vs. 2.1%) but did not reach statistical significance (p=0.06). The FDA recommends caution when combining icosapent ethyl with anticoagulants or dual antiplatelet therapy.

Do higher EPA blood levels predict better outcomes?

Yes. A biomarker substudy showed a dose-response relationship between on-treatment serum EPA levels and MACE reduction, supporting EPA itself (not triglyceride lowering) as the primary driver of benefit.

What do current guidelines say about icosapent ethyl?

The ACC, AHA, and ESC/EAS all recommend considering icosapent ethyl (Class IIa or equivalent) for residual cardiovascular risk in statin-treated patients with persistently elevated triglycerides (generally 135 to 499 mg/dL).

Is generic icosapent ethyl available?

Yes. Generic versions became available in 2020 following patent litigation, improving access and reducing cost barriers that limited initial uptake.

Should icosapent ethyl be combined with PCSK9 inhibitors?

No dedicated outcomes trial has tested this combination. The decision to add icosapent ethyl to PCSK9 inhibitor therapy is based on clinical judgment and extrapolation from subgroup data, not direct randomized evidence.

REDUCE-IT Extension Data and What Happened After the Trial Ended

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | Trial | REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl, Intervention Trial) | | N | 8,179 | | Intervention | Icosapent ethyl 4 g/day (2 g twice daily) | | Comparator | Mineral oil placebo | | Median follow-up | 4.9 years | | Primary endpoint | 5-point MACE (CV death, nonfatal MI, nonfatal stroke, coronary revascularization, unstable angina requiring hospitalization) | | Key result | HR 0.75; 95% CI 0.68, 0.83; p <0.001 (Bhatt et al., NEJM 2019) |

Why the Original Trial Left Questions Open

The primary REDUCE-IT publication reported a 25% relative risk reduction in the first occurrence of the 5-point MACE composite. That result was statistically decisive. But several clinically important questions remained unanswered at the time of the 2018 AHA presentation and subsequent 2019 NEJM paper.

First, did the benefit continue to accrue over time, or was there a plateau? Second, was the effect durable across total (not just first) events, given that patients at residual cardiovascular risk often experience recurrent ischemia? Third, did new safety concerns surface with extended exposure to high-dose EPA? These are the questions that follow-up analyses, prespecified substudies, and real-world pharmacovigilance have since addressed.

Time-Course Analysis: When Did the Benefit Start?

A prespecified landmark analysis examined event curves at 12, 24, 36, and 48 months. The Kaplan-Meier curves for the primary endpoint began separating within the first year and continued to diverge throughout the trial period (Bhatt et al., NEJM 2019). By month 12, the absolute risk difference was already measurable. By year 5, the number needed to treat (NNT) for the primary composite endpoint was approximately 21.

This early separation matters clinically. It argues against a slow, lipid-modification-only mechanism. Triglyceride lowering with icosapent ethyl was substantial (median reduction of ~18% vs. an increase in the placebo arm), yet the magnitude of MACE reduction far exceeded what triglyceride change alone would predict based on Mendelian randomization data. The early divergence is consistent with pleiotropic effects: membrane stabilization, anti-inflammatory action, reduced platelet aggregation, and improved endothelial function.

HealthRX Durability Framework: Assessing Whether a Trial Signal Holds

We evaluate post-trial durability across four axes:

| Axis | REDUCE-IT Status | |---|---| | Curve trajectory | Diverging through 5+ years, no plateau observed | | Total-events analysis | Confirmed (HR 0.70 for total events, stronger than first-event) | | Biomarker concordance | Partial (TG reduction explains ~part of benefit; EPA level is the stronger correlate) | | Independent replication | Partially challenged by STRENGTH trial (mixed EPA/DHA, corn oil placebo, no benefit) |

This framework helps distinguish trials where the primary result was a snapshot from those where extended observation reinforces the original conclusion. REDUCE-IT falls into the latter category, though with important caveats about the placebo arm.

Total Events Analysis: Beyond the First MACE

One of the most cited follow-up papers examined total ischemic events, not just first occurrences. Published in the Journal of the American College of Cardiology in 2019, this prespecified analysis found that icosapent ethyl reduced total primary endpoint events by 30% (rate ratio 0.70; 95% CI 0.62, 0.78; p <0.001).

This is a stronger signal than the first-event analysis. The clinical interpretation is straightforward: patients on icosapent ethyl who had an initial event were also less likely to have a second or third event. In a population with established atherosclerotic disease or diabetes plus additional risk factors, recurrent events drive a large share of morbidity, hospital costs, and mortality. The total-events finding strengthened the economic and clinical case for long-term treatment.

| Endpoint | First Event HR (95% CI) | Total Events RR (95% CI) | |---|---|---| | 5-point MACE | 0.75 (0.68, 0.83) | 0.70 (0.62, 0.78) | | CV death, MI, stroke | 0.74 (0.65, 0.83) | 0.71 (0.62, 0.82) | | CV death | 0.80 (0.66, 0.98) |, |

Data from Bhatt et al., NEJM 2019 and the total-events JACC analysis.

The Mineral Oil Placebo Debate

No discussion of REDUCE-IT follow-up is complete without addressing the mineral oil question. The placebo capsules contained mineral oil, chosen for organoleptic matching (taste, appearance, and consistency). Post hoc analyses revealed that patients in the placebo arm experienced increases in LDL-C (~10.2 mg/dL), hsCRP (~37%), and Lp-PLA2 relative to baseline.

Critics argued that mineral oil inflated the apparent benefit of icosapent ethyl by worsening outcomes in the control arm. This concern was significant enough that the European Medicines Agency (EMA) declined approval in 2021, citing an inability to quantify the placebo contribution to the observed treatment effect.

The FDA took a different position. In its 2019 review and approval of Vascepa's CV indication, the agency acknowledged the mineral oil issue but concluded that the magnitude of MACE reduction (25%) was too large to be explained by modest LDL and CRP changes in the placebo arm alone. Sensitivity analyses adjusting for on-trial LDL changes attenuated the HR modestly (from 0.75 to approximately 0.78 to 0.80 in various models) but did not eliminate statistical significance.

A third-party meta-regression published in 2021 estimated that mineral oil may have contributed 3, 5 percentage points to the relative risk reduction, meaning the "true" benefit might be closer to 20 to 22% rather than 25%. This remains debated, and no definitive external dataset has resolved the question.

EPA Levels as a Predictor of Benefit

A biomarker substudy examined on-treatment EPA levels and their relationship to outcomes. Patients in the icosapent ethyl arm who achieved higher serum EPA concentrations experienced greater MACE reductions (Bhatt et al., Circulation 2020). The median on-treatment EPA level in the active arm was approximately 144 µg/mL, roughly four times baseline.

This dose-response relationship has clinical implications. It suggests that therapeutic drug monitoring of EPA levels could, in theory, identify non-responders or patients with poor adherence. It also supports the mechanistic argument that EPA itself (not triglyceride lowering per se) drives the cardiovascular benefit, since triglyceride reduction and EPA levels were not perfectly correlated.

STRENGTH Trial: The Shadow Over Replication

The STRENGTH trial (2020, JAMA) tested a different omega-3 formulation (carboxylic acid form of EPA + DHA, 4 g/day) against a corn oil placebo in a similar high-risk population. It was stopped early for futility. No MACE reduction was observed (HR 0.99; 95% CI 0.90, 1.09).

Two differences from REDUCE-IT are commonly cited to explain the discrepancy. First, STRENGTH used EPA plus DHA rather than EPA alone. Preclinical data suggest DHA may partially counteract EPA's membrane-stabilizing effects and raise LDL-C. Second, STRENGTH used corn oil (biologically inert) rather than mineral oil, removing any possible placebo-mediated harm.

The divergence between REDUCE-IT and STRENGTH remains one of the most actively discussed topics in cardiovascular pharmacotherapy. Proponents of icosapent ethyl point to the EPA-only mechanism and the dose-response biomarker data. Skeptics view STRENGTH as evidence that the mineral oil placebo was a meaningful confounder. Neither camp has produced a definitive resolution.

Safety Signals with Extended Exposure

The original trial reported a statistically significant increase in atrial fibrillation (5.3% vs. 3.9%) and a non-significant trend toward increased serious bleeding (2.7% vs. 2.1%) in the icosapent ethyl arm. Post-marketing pharmacovigilance and the Vascepa prescribing information now include these warnings.

| Safety Signal | Icosapent Ethyl | Placebo | p-value | |---|---|---|---| | Atrial fibrillation/flutter | 5.3% | 3.9% | 0.003 | | Serious bleeding | 2.7% | 2.1% | 0.06 | | Peripheral edema | 6.5% | 5.0% | 0.002 |

The atrial fibrillation signal is consistent with older data on high-dose fish oil. A 2021 meta-analysis of omega-3 cardiovascular trials confirmed a dose-dependent increase in AF risk across formulations (Gencer et al., Circulation 2021). For patients with a history of AF or those on antiarrhythmic therapy, this signal warrants individualized risk-benefit discussion.

Bleeding events did not reach statistical significance in REDUCE-IT, but the numerical increase prompted the FDA to recommend caution when combining icosapent ethyl with anticoagulants or antiplatelet agents beyond aspirin. No new safety signals emerged in longer-term pharmacovigilance through 2025 that were not already identified during the trial.

Guideline Uptake and Real-World Adoption

Following FDA approval and the totality of evidence, multiple cardiology societies incorporated icosapent ethyl into treatment algorithms:

The 2019 ESC/EAS dyslipidemia guidelines gave a Class IIa recommendation for icosapent ethyl in statin-treated patients with triglycerides 135 to 499 mg/dL.
The 2021 ACC Expert Consensus Decision Pathway recommended considering icosapent ethyl for residual cardiovascular risk reduction when triglycerides remain elevated despite statin therapy.
The AHA/ACC 2018 cholesterol guidelines (updated commentary) acknowledged REDUCE-IT as the first omega-3 trial to demonstrate MACE reduction.

Real-world prescription data showed rapid initial uptake following approval, followed by a plateau partly attributed to cost and insurance coverage barriers. Generic icosapent ethyl became available in 2020 after patent litigation, which expanded access but also reduced the commercial incentive for additional manufacturer-sponsored follow-up studies.

What We Still Do Not Know

Several gaps persist. No randomized extension study tracked patients beyond the original 4.9-year median. Observational registries have not published large cohort follow-up data on patients who continued versus discontinued icosapent ethyl after the trial. The question of whether benefit persists, accumulates, or reverses upon discontinuation remains unanswered.

The interaction between icosapent ethyl and newer therapies (PCSK9 inhibitors, inclisiran, bempedoic acid) has not been tested in dedicated outcomes trials. For patients already on maximally intensified lipid-lowering therapy, the incremental value of adding icosapent ethyl is extrapolated from subgroup analyses rather than proven in a standalone trial.

Frequently asked questions

›

References

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. PubMed
Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events. J Am Coll Cardiol. 2019;73(22):2791-2802. PubMed
Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH). JAMA. 2020;324(22):2268-2280. PubMed
Vascepa (icosapent ethyl) Prescribing Information. Amarin Pharma, Inc. 2019. FDA Label
Gencer B, Djousse L, Al-Ramady OT, et al. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation. Circulation. 2021;144(25):1981-1990. PubMed